Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023

未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場2019-2023

◆タイトル:Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023
◆商品コード:IRTNTR31275
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年5月16日
◆ページ数:118
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:Health Care
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場について調査・分析し、市場概要、市場環境、未分化リンパ腫キナーゼ反応(ALK)抑制剤市場規模、タイプ別(次世代ALK阻害剤、初代ALK阻害剤、第三世代ALK阻害剤)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場概要
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場環境
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場動向
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場規模
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場:業界構造分析
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場:タイプ別(次世代ALK阻害剤、初代ALK阻害剤、第三世代ALK阻害剤)
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場:地域別市場規模・分析
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の北米市場規模・予測
・未分化リンパ腫キナーゼ反応(ALK)抑制剤のヨーロッパ・中東・アフリカ市場規模・予測
・未分化リンパ腫キナーゼ反応(ALK)抑制剤のアジア太平洋市場規模・予測
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の主要国分析
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場:意思決定フレームワーク
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場:成長要因、課題
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場:競争環境
・未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場:関連企業情報(ベンダー分析)

About this market

The high prevalence of lung cancer is one of the key factors expected to trigger the market growth during the forecast period. The increasing need for treatments coupled with the advances in therapeutics such as targeted therapy is encouraging more and more patients to undergo treatments using ALK inhibitor therapeutics. As a result, owing to the strong incidence rates of the disease and the increasing drug approvals, global ALK inhibitors market will register considerable growth during the forecast period. Technavio’s analysts have predicted that the anaplastic lymphoma kinase (ALK) inhibitors market will register a CAGR of about 21% by 2023.

Market Overview

Presence of patient assistance programs

Patient assistance programs and reimbursement programs are expected to help with the high-cost regimen of ALK inhibitors to a large extent, which would encourage more patients to avail the treatment, thereby driving the market growth.

Adverse effects associated with therapeutics

Despite being highly efficacious, ALK inhibitors used for treatment NSCLC are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.

For the detailed list of factors that will drive and challenge the growth of the anaplastic lymphoma kinase (ALK) inhibitors market during 2019-2023, view our report.

Competitive Landscape

The market appears to be concentrated with the presence of a few market players. ALK inhibitors have demonstrated efficacy in the oncology indications such as NSCLC, which has been encouraging vendors to extend their application to various other oncology indications through additional clinical trials. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Second-generation ALK inhibitors – Market size and forecast 2018-2023

First-generation ALK inhibitors – Market size and forecast 2018-2023

Third-generation ALK inhibitors – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

F. Hoffmann-La Roche Ltd.

Novartis AG

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Type – Market share 2018-2023 (%)

Exhibit 18: Comparison by type

Exhibit 19: Second-generation ALK inhibitors – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Second-generation ALK inhibitors – Year-over-year growth 2019-2023 (%)

Exhibit 21: Second-generation ALK inhibitors pipeline

Exhibit 22: First-generation ALK inhibitors – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Upcoming patent expiry of XALKORI

Exhibit 24: First-generation ALK inhibitors – Year-over-year growth 2019-2023 (%)

Exhibit 25: Third-generation ALK inhibitors – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: Lorlatinib pipeline

Exhibit 27: Third-generation ALK inhibitors – Year-over-year growth 2019-2023 (%)

Exhibit 28: Market opportunity by type

Exhibit 29: Customer landscape

Exhibit 30: Market share by geography 2018-2023 (%)

Exhibit 31: Geographic comparison

Exhibit 32: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: North America – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in North America

Exhibit 35: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Europe

Exhibit 38: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in Asia

Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 43: Top 3 countries in ROW

Exhibit 44: Key leading countries

Exhibit 45: Market opportunity

Exhibit 46: Patient assistance programs

Exhibit 47: Alternative therapies for oncology conditions

Exhibit 48: Side effects of ALK inhibitors

Exhibit 49: Impact of drivers and challenges

Exhibit 50: Drugs with respect to their expanded indications

Exhibit 51: Vendor landscape

Exhibit 52: Landscape disruption

Exhibit 53: Vendors covered

Exhibit 54: Vendor classification

Exhibit 55: Market positioning of vendors

Exhibit 56: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 57: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 58: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 59: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 60: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 61: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 62: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 63: Novartis AG – Vendor overview

Exhibit 64: Novartis AG – Business segments

Exhibit 65: Novartis AG – Organizational developments

Exhibit 66: Novartis AG – Geographic focus

Exhibit 67: Novartis AG – Segment focus

Exhibit 68: Novartis AG – Key offerings

Exhibit 69: Novartis AG – Key customers

Exhibit 70: Pfizer Inc. – Vendor overview

Exhibit 71: Pfizer Inc. – Business segments

Exhibit 72: Pfizer Inc. – Organizational developments

Exhibit 73: Pfizer Inc. – Geographic focus

Exhibit 74: Pfizer Inc. – Segment focus

Exhibit 75: Pfizer Inc. – Key offerings

Exhibit 76: Pfizer Inc. – Key customers

Exhibit 77: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 78: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 79: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 80: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 81: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 82: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 83: Validation techniques employed for market sizing

Exhibit 84: Definition of market positioning of vendors



【掲載企業】

F. Hoffmann-La Roche Ltd.、Novartis AG、Pfizer Inc.、Takeda Pharmaceutical Co. Ltd.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[未分化リンパ腫キナーゼ反応(ALK)抑制剤の世界市場2019-2023]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆